Healio11h
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
The American Journal of Managed Care13h
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
centerforbiosimilars17h
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Contract Pharma18h
FDA Approves Celltrion’s Biosimilar to ACTEMRA
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
ENDPOINTS NEWS18h
Cell­tri­on looks to buy US fa­cil­i­ties to side­step po­ten­tial Trump tar­iffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...
Inflammatory Bowel Disease Treatment Market Size Predicted To Hit USD 34.5 Billion By 2031 At 5.1% CAGR, Says AMR
Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...